Orgenesis Secures $10M For Potential Diabetes Cure, Retains Ownership Of MaSTherCell

December 28, 2015 | Orgenesis, an Israeli-founded biotech company specialized in diabetes treatment, has raised $10 million in new financing and, per a prior agreement, allows Orgenesis to fulfill its obligation to finalize the acquisition of MaSTherCell, a Belgian Contract Development and Manufacturing Organization (CDMO) specialized in cell therapy development for advanced medicinal products. Following the transaction, MaSTherCell will continue to function and be managed as a separate bio-manufacturing company. Founded in 2008 by Sarah Ferber, Head of the Endocrine Research unit at Sheba Medical Center in Israel, Orgenesis has developed a novel and patented cell therapy called “cellular trans-differentiation” that converts patients’ own cells into functioning insulin-producing cells as a treatment for diabetes. Continued development of this regenerative medicine could potentially provide a cure for Type 1 Diabetes.